150 related articles for article (PubMed ID: 35252267)
1. Short-Term Efficacy in Polypoidal Choroidal Vasculopathy Patients Treated With Intravitreal Aflibercept or Conbercept.
Xue Y; Qinhua C
Front Med (Lausanne); 2022; 9():835255. PubMed ID: 35252267
[TBL] [Abstract][Full Text] [Related]
2. Improvements of Retinal Sensitivity after Intravitreal Injection of Aflibercept in Eyes with Neovascular Age-Related Macular Degeneration with or without Polypoidal Choroidal Vasculopathy.
Nizawa T; Kitahashi M; Baba T; Iwase T; Kubota-Taniai M; Hattori Y; Shiko Y; Kawasaki Y; Iwase T; Sato T; Ogawa S; Sugawara T; Yamamoto S
Ophthalmologica; 2021; 244(4):347-360. PubMed ID: 34015785
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal Aflibercept and Ranibizumab Injections for Polypoidal Choroidal Vasculopathy.
Cho HJ; Kim KM; Kim HS; Han JI; Kim CG; Lee TG; Kim JW
Am J Ophthalmol; 2016 May; 165():1-6. PubMed ID: 26921806
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy.
Miyakubo T; Mukai R; Matsumoto H; Morimoto M; Takahashi M; Nagai K; Nakamura K; Hoshino J; Akiyama H
Clin Ophthalmol; 2023; 17():571-577. PubMed ID: 36817637
[TBL] [Abstract][Full Text] [Related]
5. One-year outcomes of intravitreal conbercept combined rescue therapy for polypoidal choroidal vasculopathy in a Chinese population: a real-life clinical data.
Qi HJ; Jin EZ; Zhao MW
Int J Ophthalmol; 2019; 12(1):51-57. PubMed ID: 30662840
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the Efficacy of Three Loading Doses of Intravitreal Injection of Conbercept with Injection Combined with PDT for the Treatment of PCV.
Li F; Ma A; Zhao B
Biomed Res Int; 2020; 2020():2428348. PubMed ID: 32382537
[TBL] [Abstract][Full Text] [Related]
7. Comparison of one-year results of photodynamic therapy combined with ranibizumab or aflibercept for treating polypoidal choroidal vasculopathy.
Ito A; Maruyama-Inoue M; Kitajima Y; Sato S; Inoue T; Yamane S; Kadonosono K
PLoS One; 2020; 15(6):e0235213. PubMed ID: 32579608
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy.
Fukuda Y; Sakurada Y; Matsubara M; Hasebe Y; Sugiyama A; Kikushima W; Kashiwagi K
Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572350
[TBL] [Abstract][Full Text] [Related]
9. One-Year Outcomes following Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in Japanese Patients: The APOLLO Study.
Oshima Y; Kimoto K; Yoshida N; Fujisawa K; Sonoda S; Kubota T; Murata T; Sakamoto T; Yoshida S; Sonoda KH; Ishibashi T
Ophthalmologica; 2017; 238(3):163-171. PubMed ID: 28697497
[TBL] [Abstract][Full Text] [Related]
10. The comparison of two different strategies of intravitreal conbercept for polypoidal choroidal vasculopathy in Chinese patients results from a 48-week randomized phase 4 study: STAR study.
Li X; Qu J; Su G; Yu S; Zhang Y; Sadda SV;
Acta Ophthalmol; 2023 May; 101(3):e327-e337. PubMed ID: 36259089
[TBL] [Abstract][Full Text] [Related]
11. Short-term efficacy of intravitreal aflibercept for patients with treatment-naïve polypoidal choroidal vasculopathy.
Ijiri S; Sugiyama K
Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):351-7. PubMed ID: 25023147
[TBL] [Abstract][Full Text] [Related]
12. AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY: As Needed Versus Fixed Interval Dosing.
Inoue M; Yamane S; Taoka R; Arakawa A; Kadonosono K
Retina; 2016 Aug; 36(8):1527-34. PubMed ID: 26710307
[TBL] [Abstract][Full Text] [Related]
13. One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy.
Weng HY; Huang TL; Chang PY; Wang JK
BMC Pharmacol Toxicol; 2019 May; 20(1):29. PubMed ID: 31088543
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
Ogasawara M; Koizumi H; Yamamoto A; Itagaki K; Saito M; Maruko I; Okada AA; Iida T; Sekiryu T
Jpn J Ophthalmol; 2018 Sep; 62(5):584-591. PubMed ID: 29974277
[TBL] [Abstract][Full Text] [Related]
15. SHORT-TERM EFFICACY OF CONBERCEPT AND RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
Huang Z; Ding Q; Yan M; Lian H; Chen Z; Chen X; Song Y
Retina; 2019 May; 39(5):889-895. PubMed ID: 29360683
[TBL] [Abstract][Full Text] [Related]
16. One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
Matsumiya W; Honda S; Otsuka K; Miki A; Nagai T; Imai H; Kusuhara S; Nakamura M
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):541-548. PubMed ID: 27687988
[TBL] [Abstract][Full Text] [Related]
17. One-Year Efficacy and Safety of Proton-Beam Irradiation Combined with Intravitreal Conbercept for Refractory or Recurrent Polypoidal Choroidal Vasculopathy: A Pilot Study.
Guo J; Qiu X; Tang W; Xu G; Moyers MF; Ren W; Xing Y; Gao J; Sun J; Lu J; Kong L; Liu W
Ophthalmol Ther; 2022 Feb; 11(1):187-199. PubMed ID: 34773572
[TBL] [Abstract][Full Text] [Related]
18. Short-term efficacy of intravitreal aflibercept in treatment-naive patients with polypoidal choroidal vasculopathy.
Inoue M; Arakawa A; Yamane S; Kadonosono K
Retina; 2014 Nov; 34(11):2178-84. PubMed ID: 25046397
[TBL] [Abstract][Full Text] [Related]
19. Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy.
Peng Y; Zhang X; Li M; Liu B; Mi L; Zuo C; Wen F
Drug Des Devel Ther; 2018; 12():339-345. PubMed ID: 29497280
[TBL] [Abstract][Full Text] [Related]
20. Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy.
Jeong S; Sagong M
Br J Ophthalmol; 2017 Jun; 101(6):758-763. PubMed ID: 27597740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
